Sodium Butyrate For Improving Cognitive Function In Schizophrenia

Last updated: January 15, 2019
Sponsor: Shanghai Mental Health Center
Overall Status: Trial Not Available

Phase

2/3

Condition

Learning Disorders

Tourette's Syndrome

Psychosis

Treatment

N/A

Clinical Study ID

NCT03010865
2016-12
  • Ages 18-60
  • All Genders

Study Summary

The purpose of this grant is to evaluate the efficacy of sodium butyrate as a novel treatment for cognitive deficits in schizophrenia (SZ). The aims will be to evaluate its effects on improving symptoms and functioning in SZ, and the relationship of the drug's clinical effects to epigenetic and inflammation related biochemical changes.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Subjects who have cognitive deficits as indicated by a score of < 85 on RBANS,

  2. meet criteria for DSM-5 diagnosis of chronic SZ, schizoaffective disorder (SA),

  3. Subjects who are stably treated with antipsychotic medications and are not in acuteexacerbation of illness symptoms.

Exclusion

Exclusion Criteria:

  1. History of mental retardation or pervasive developmental disorder,

  2. Subjects with a current serious neurological/CNS disorder (such as seizure disorder,stroke or multiple sclerosis) or brain trauma,

  3. Current treatment with valproic acid, butyrate drugs, sulforaphane, or other drugs orchemicals known to have high HDAC inhibitory activity,

  4. Pregnancy,

  5. Severe unstable medical condition,

  6. Current suicidal or homicidal thoughts,

  7. Current alcohol or substance abuse (other than nicotine or occasional marijuana) inthe last month.

Study Design

Study Start date:
June 01, 2017
Estimated Completion Date:
February 29, 2020

Study Description

The persistent cognitive deficits which can be appreciated across the course of SZ, from prodromal to chronic SZ, may be the most important underlying dysfunction in preventing functional, occupational, and social recovery in SZ compared to other symptom domains. Sodium butyrate is a short chain fatty acid and binds to the zinc site of histone deacetylases (HDAC). The inhibition of HDAC results in histone hyperacetylation. This study aims to evaluate its effects on improving symptoms and functioning in SZ, and the relationship of the drug's clinical effects to epigenetic and inflammation related biochemical changes.

The proposed study will be a double blind study of the effects of sodium butyrate on cognitive function and symptoms in chronic SZ patients showing continued cognitive deficits.The primary specific aims of the proposal will be to test the the MATRICS (MCCB) battery,delayed recall performance, and performance on real world functional tasks as assessed by the USCD Performance- Based Skills Assessment Battery (UPSA). In addition, we will also investigate whether sodium butyrate may improve other aspects of cognition.

We will also explore whether improvement in cognition is related to change in HDAC activity in peripheral blood cells and changes in inflammatory makers in the blood, and assess whether there is any improvement in psychopathology as measured by PANSS scale.

Connect with a study center

  • Shanghai Mental Health Center

    Shanghai, Shanghai 200030
    China

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.